CD49c Antibody, anti-human, REAfinity™
Synonyms: ITGA3, MSK18, FRP-2, GAP-B3, GAPB3, ILNEB, VCA-2, VL3A, VLA-3α
RECOMBINANT EXTENDED VALIDATION
Bioz Star94/100 Bioz rating
4 Citations1 Image
Clone:
REA360 | ASC-1
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
FC, MICS, IF, IHC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »
Select a conjugate:
Select a size:
Other sizes

Related products for CD49c Antibody, anti-human, REAfinity™

Flow cytometry applications
APC
APC-Vio 770
Biotin
FITC
PE
PE-Vio 770
PerCP-Vio 700
VioBlue
Recommended dilution:
1:50
Remark:
Cells should be stained prior to fixation, if formaldehyde is used as a fixative.
Data source:
Miltenyi Biotec
Conjugate:
APC
Used products:
130-134-107, 130-134-164
Description:
HeLa cells were stained with CD49c antibodies or with the corresponding REA Control (S) antibodies (left peak) and analyzed by flow cytometry using the MACSQuant® Analyzer. The Tandem Signal Enhancer has been used to increase binding specificity of tandem-dye–conjugated antibodies. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide fluorescence or 4',6-diamidino-2-phenylindole (DAPI) fluorescence, as in the case of tandem conjugates.

Application image
MICS (MACSima Imaging Cyclic Staining) applications
APC
FITC
PE
Fixation:
frozen – Acetone
Species tested:
human
Recommended dilution:
1:50
Data source:
Miltenyi Biotec
Conjugate:
APC
Used products:
130-134-107, 130-134-164
Testing grade:
Extended validation for CD49c Antibody, anti-human, REAfinity™
Specificity
Epitope competition assay

In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.

Other clones
Overlap in epitope recognition with REA360
REAL349
high
C3 II1
high
17c6
partial
ASC-1
partial
P1B5
high

Cells were incubated with an excess of purified unconjugated CD49c (REA360) antibody followed by staining with fluorochrome-conjugated antibodies from other known clones targeting the same antigen. Fluorescence intensity was then used to assess epitope overlap: a minimal or absent signal indicated high epitope overlap, an intermediate signal suggested partial overlap, and a strong signal reflected low overlap.

Knockout validation

To ensure antibody specificity, the target gene is knocked out in a suitable cell line using the CRISPR/Cas9 system and the knockout is confirmed by sequencing of the target locus. The antibody is considered to bind specifically to the intended epitope if no antibody binding to the knockout cells can be detected. The antibody staining is controlled by fluorescence microscopy and/or flow cytometry.

WT
Extended-Validation detailed information image
KO
Extended-Validation detailed information image

Fluorescence microscopy image of CD49c knockout cells. Wild type (WT, left) and knockout cells (KO, right) were stained with CD49c-PE (REA360, red) and counterstained with DRAQ5 (blue) as DNA stain.

Extended-Validation detailed information image

Overlay histogram showing flow cytometric analysis of CD49c knockout cells. Wild type (red) and knockout cells (blue) were stained with CD49c-PE, clone (REA306). Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells and cell doublets were excluded from the analysis based on scatter signals and propidium iodide fluorescence.

Sensitivity
Performance comparison

Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.

Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image

Flow cytometric comparison of different clones for CD49c. Hela cells were stained with CD49c antibodies and with a suitable counterstaining. As a control, CD49c antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and propidium iodide fluorescence.The recommended titers of respective antibodies from different suppliers were used.

Fixation data

To provide an indication on how an antibody performs after fixation of cells, in-house data on staining results before and after fixation with 3.7% formaldehyde using Miltenyi Biotec antibodies are provided. Different experimental settings may lead to different results.

No fixation
Extended-Validation detailed information image
Post fixation
Extended-Validation detailed information image

Comparison of staining pattern on non-fixed and fixed cells using CD49c (REA360). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.

Specifications for CD49c Antibody, anti-human, REAfinity™
Overview

Clone REA360 recognizes the human CD49c antigen, a single-pass type I membrane protein also known as integrin α-3 (ITGA3) or VLA-3α. CD49c forms a heterodimer with integrin β1 (α3β1, CD49c/CD29, VLA-3) and plays a role in neural migration and corticogenesis, acted upon by such factors as netrin-1 and reelin. It is expressed by many types of adhesion cells, such as endothelial cells, epithelial cells, and dermal fibroblasts. Weak expression has been reported on leukocytes. CD49c/CD29 plays a role in cell-cell and cell-matrix adhesion through binding fibronectin, laminin, collagen, epiligrin, thrombospondin, and CSPG4.

Additional information: Clone REA360 displays negligible binding to Fc receptors.

Alternative names

ITGA3, MSK18, FRP-2, GAP-B3, GAPB3, ILNEB, VCA-2, VL3A, VLA-3α

Detailed product information

Technical specifications

Clone
REA360
Clonality
monoclonal
Isotype
recombinant human IgG1
Isotype control
REA Control Antibody (S), human IgG1
Host
human cell line
Type of antibody
Primary antibodies, Recombinant antibodies
Species reactivity
human
Antigen
CD49c
Molecular mass of antigen [kDa]
113, sum of molecular weights of subunits
Distribution of antigen
epithelial cells, fibroblasts, leukocytes
Entrez Gene ID
RRID
AB_2658479, AB_2658480, AB_2658485, AB_2658492, AB_2658486, AB_2658490, AB_2658488, AB_2658493, AB_2751548, AB_2658494, AB_2751538, AB_2658489, AB_2658487, AB_2658491

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for CD49c Antibody, anti-human, REAfinity™
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support

You have previously chosen International as your location.
What do you want to do?